Non-invasive solution 60 seconds treatment Various disease areas Safety study & Efficacy
Contact Us
start EXPLORING

MeticTouch®

Non-invasive Ultrasound Ocular Drug Delivery Platform

Our Vision

CHANGING THE TREATMENT PARADIGM FOR OCULAR DISEASE MANAGEMENT

Enhance accessibility
and comfort

Potential to replace invasive & complicated surgical procedures

Short treatment
within 60 seconds

Just a 60 seconds touch & induction process

discover more

Designed for Various
Disease Areas

Research on major eye diseases such as Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Non-Infectious Uveitis (NIU), and many others

Excellent in compatibility

Ranging from small molecules up to 150kDa macromolecules

discover more

Safety study & efficacy

No observable safety issue, with baseline-comparable results in preclinical studies

discover more

Novel ultrasound
drug induction system

Compatible to
wide range of APIs

MeticTouch®
Leading in advanced
Ocular Treatment Model

Profiles proven in
preclinical trials

Patent portfolio in
13 major countries

Demonstrated efficacy
and bioavailability
with multiple drug products

Unmet Needs

Non-invasive Solution
Improving Life without needles

 

Problems of Traditional Eye injections:

  • Current first-line posterior drug delivery focus on invasive injections
  • Lack of emphasis on the improvement of patient experience in current research field
  • Injections consist of complicated and resource-intensive pre-surgical & post-surgical procedures
  • Up to 50% of patients opting out of injection treatments

Solutions provided by MeticTouch®:

  • A non-invasive and effective option to replace eye injections
  • Compatible with wide range of APIs
  • Highly reduces risks and complications in treatment procedures
  • Patient-centred solution to enhance treatment compliance and adhereance

60 seconds treatment

Treatment procedure
Reducing the operation process

Ultrasound treatment has a shorten total patient involved time, compared to traditional eye injection.

0
sec

 

TRADITIONAL EYE INJECTION ULTRASOUND TREATMENT
PRE-OPERATION ACTIVITIES

1. Seat patient and brief

2. Apply anesthetic and disinfectant drops

3. Covered and secured region of interest with drape

1. Turn on device and select from pre-set treatment protocols

2. Prepare single-use drug applicator and attached to device

*All pre-operation activities in ultrasound treatment only involve HCPs.
OPERATION ACTIVITIES

1. Place speculum onto patient eyes

2. Apply local anesthetic with swap

3. Mark injection site (3.5mm from limbus)

4. Instruct patient to look to one side and keep eye/head still

5. Inject into patient's eye

6. Hold cotton bud at the injection site

1. Seat patient and brief

2. Apply disinfectant drops

3. Instruct patient to look to one side

4. Apply ultrasound drug induction for 60 secs
POST-OPERATION ACTIVITIES

1. Apply antibiotics eye drops

2. Remove drape and speculum

3. Debrief

1. Debrief
TOTAL PATIENT INVOLVED TIME
10 mins 5 mins
* Treatment procedure subject to regulatory approval.

How it works

MeticTouch® revolutionizing drug delivery in ophthalmology

Mechanism of Action visualization

MeticTouch® AIMS TO BECOME THE NEW STANDARD OF CARE IN DRUG DELIVERY FOR OCULAR DISEASE MANAGEMENT

process 1

MeticTouch® approaches the eye

process 2

With low-frequency ultrasound, changes in acoustic pressure creates oscillating microbubbles that contracts and expands

process 3

The oscillation causes movement in the surrounding liquid and form microstreaming by shearing force

process 4

This eventually creates non-permanent micropores in the cell layer, allowing therapeutics to enter the eye, through the sclera and directly to the retina.

DIVERSED TARGET DISEASE AREAS

EXAMPLES OF TARGET INDICATIONS

Our advanced technology is highly compatible to various drug products, targeted to be applicable to a wide range of ocular diseases management, in particular to posterior diseases where injection is usually required for treatment.

 

Age-related Macular Degeneration (AMD)AMD

It is a common condition that affects the middle part of your vision. It usually first affects people in their 50s and 60s. It can make everyday activities like reading and recognising faces difficult. Without treatment, your vision may get worse. This can happen gradually over several years ("dry AMD"), or quickly over a few weeks or months ("wet AMD").The exact cause is unknown. It's been linked to smoking, high blood pressure, being overweight and having a family history of AMD.2

Diabetic Macular Edema (DME)DME

Diabetic Macular Edema (DME) is a severe complication of Diabetic retinopathy (DR) that occurs specifi­cally as a result of inadequately treated diabetes mellitus (DM), has overtaken proliferative diabetic retinopathy (DR) as the most common cause of vision impairment in individuals with diabetes mellitus (DM). In recent epidemiologic studies, approximately 30% of patients worldwide with diabetes mellitus (DM) were found to have vision-threatening Diabetic retinopathy (DR); and in the United States, 3.8% of patients were found to have DME.3

Non-Infectious Uveitis (NIU)NIU

Is a serious, sight-threatening intraocular inflammatory condition characterized by inflammation of the uvea including iris, ciliary body, and choroid.4

* Simulated vision for reference only.

COMPATIBITIY WITH MULTIPLE DRUG PRODUCTS
Our validated therapeutic molecules

MeticTouch® is proven in compatibility with major and common treatment molecules.

 

External references of common eye diseases
Common eye diseases

AMD
Age-Related Macular Degeneration



read more

DME
Diabetic Macular Edema



read more

NIU
Non-Infectious Uveitis



read more

Safety & Efficacy

Low Risk / side effect
product safety

Animal studies indicating no abnormality
after ultrasound treatment up to 6 months

Area of testing Result Ref.
Graphic
Electroretinography (ERG) Both scotopic and photopic response are comparable to baseline
Intraocular pressure (IOP) IOP are comparable to baseline
Retina thickness by optical coherence tomography (OCT) No obvious changes in retina thickness
Histology No histopathological damage observed

Frequently Asked Questions

General Public Patients Healthcare
Professionals Pharma
General Public
What is MeticTouch®, and how does it revolutionize non-invasive ocular drug delivery?
MeticTouch® is an innovative non-invasive ocular drug delivery technology that offers a patient-friendly approach to administering medications to the eye. By eliminating the need for injections, MeticTouch® improves comfort, convenience, and potentially enhances treatment outcomes.
How can MeticTouch® benefit patients with eye conditions?
MeticTouch® provides patients with a comfortable and convenient treatment option for various eye conditions. It reduces the discomfort and anxiety associated with injections, minimizes the duration of clinic visits, and potentially improves the effectiveness of drug delivery.
Who developed MeticTouch®?
The novel MeticTouch® technology is developed by Opharmic, a Hong Kong based innovative company specialised in the development of ultrasound-based solution platforms.
I am interested in the concept of MeticTouch® but not for ophthalmology applications. Are you open for discussion or partnership?
Absolutely. As innovators, we are always open to speak with like-minded people to explore opportunities in developing or help to develop novel solutions for unmet needs. Explore our common partnership models, or just contact us to start a dialogue!
I am interested in supporting MeticTouch®. How can I learn more about getting involved?
No matter if you are a patient, healthcare professional, or investor, we welcome you to get in touch with us to learn more about our company, technologies, products, and people.
Patients
How does MeticTouch® compare to traditional eye injections for patients?
MeticTouch® offers a significant improvement over traditional eye injections. It eliminates the need for needles, making the treatment more comfortable and less anxiety-inducing for patients.
What eye conditions can be treated using MeticTouch®?
MeticTouch® is a method of drug delivery and is not intended to provide therapeutic effect when used without drugs. Depending on the drug being delivered, MeticTouch® can potentially be used to treat various eye conditions, including age-related macular degeneration, diabetic macular edema, and inflammatory disorders of the eye.
How long will a MeticTouch® session typically last?
The duration of a MeticTouch® session may vary depending on factors such as the specific medication and the patient's individual needs. However, sessions are generally relatively short, typically lasting between 10 to 15 minutes.
Is MeticTouch® a one-time treatment, or will multiple sessions be required?
MeticTouch® is a method of drug delivery and is not intended to provide therapeutic effect when used without drugs. The treatment plan using MeticTouch® can vary depending on the specific eye condition and the patient's response to the treatment as judged by the physician. Typically the treatment frequency is expected to follow the approved label of the drug being administrated unless otherwise judged by the physician.
Where can I get treatments using MeticTouch®?
Although with safety and efficacy extensively proven in preclinical studies, MeticTouch® is currently under clinical development towards obtaining approvals with various regulatory authorities. If you are interested in staying updated regarding the MeticTouch® treatment, we encourage you to get in touch with us, or consulting with your healthcare provider to inquire about the availability of this innovative technology and its potential applicability to your specific medical needs.
Healthcare Professionals
How does MeticTouch® differ from traditional methods of ocular drug administration?
MeticTouch® represents a significant advancement in ocular drug delivery by providing a non-invasive approach. Unlike traditional methods such as injections, MeticTouch® uses innovative ultrasound technology to create temporary openings in the scleral cell layer, facilitating precise and targeted drug delivery.
What are the research outcomes and effectiveness of MeticTouch®?
Research outcomes and effectiveness of MeticTouch® have shown promising results in various eye conditions. Extensive pre-clinical studies and user interviews have demonstrated improved patient comfort, enhanced drug delivery efficiency, and potential benefits in terms of treatment outcomes. Further research is ongoing to establish its efficacy across a broader range of indications.
Are there any specific patient selection criteria for MeticTouch®?
The non-invasive MeticTouch® is generally considered less stringent in patient criteria in comparison to the common intravitreal injections. However, common for most medical treatments, patient selection criteria for MeticTouch® may vary based on the specific condition and the characteristics of the patient. Factors such as medication properties and patient suitability play a role in determining the appropriateness of MeticTouch®.
What are the potential advantages of MeticTouch® for healthcare professionals?
MeticTouch® offers healthcare professionals several advantages. It provides a patient-friendly treatment option, potentially improving patient compliance and treatment outcomes. MeticTouch®'s precise drug delivery mechanism and targeted approach may enhance therapeutic efficacy, and its non-invasive nature reduces the associated risks and complications of injections.
Are there any ongoing research initiatives related to MeticTouch®?
Yes, there are several ongoing research initiatives related to MeticTouch®. These studies aim to further evaluate its safety, efficacy, and potential applications across various eye conditions. Follow our latest company news for data announcements, conference presentations, and more.
Pharma
What therapeutic areas or eye conditions does MeticTouch® target?
Primarily focused to replace injections, MeticTouch® targets a broad range of therapeutic areas and posterior indications. Extensive research have also shown MeticTouch®’s effectiveness in other ocular tissues such as conjunctiva, cornea, and eyelid. Deliveries of other innovative treatments or formulations are also under on-going study.
What preclinical or clinical data do you have regarding the efficacy and safety of your technology?
We have accumulated extensive preclinical data demonstrating the efficacy and safety of our non-invasive ocular drug delivery technology. These data showcase its potential to enhance drug delivery efficiency, improve patient compliance, and achieve positive treatment outcomes. If you are interested in specific research, we welcome you to get in touch with us to learn the detailed information and discuss with us on the results.
How does MeticTouch® compare to existing drug delivery methods in terms of efficacy and patient experience?
The novel MeticTouch® eliminates the need for invasive injections, potentially improving patient compliance and reducing associated discomfort and risks. Our technology also aims to enhance drug delivery efficiency and provide a more patient-friendly treatment option.
Are you open to collaboration or licensing opportunities with pharmaceutical companies?
Yes, we firmly believe that partnering with established industry players can accelerate the development, regulatory processes, and market adoption of MeticTouch®. We welcome discussions to explore potential collaborations and mutually beneficial partnerships. Explore our common partnership models or contact us directly.
What is the current stage of development and commercialization readiness of MeticTouch®?
Our non-invasive ocular drug delivery technology has reached an advanced stage of development. We have conducted extensive preclinical studies, gathering valuable data and optimizing the technology. We are actively pursuing commercialization strategies and are open to discussions regarding partnerships and market entry plans.